检索结果-南通市图书馆

Recent trends in bone metastasis treatments:A historical comparison using the new Katagiri score system

World Journal of Clinical Cases 2024年第15期12卷 2499-2505页

作者： Kenji Matsuda Kazuhiro Shimazu Hanae Shinozaki Koji Fukuda Taichi Yoshida daiki taguchi Kyoko Nomura Hiroyuki Shibata Department of Clinical Oncology Akita University Graduate School of MedicineAkita 010-8543Japan Department of Environmental Health Science and Public Health Akita University Graduate School of MedicineAkita 010-8543Japan Department of Comprehensive Cancer Control Akita University Graduate School of MedicineAkita 010-8543Japan

BACKGROUND Bone metastasis has various negative *** of daily living(ADL)and quality of life(QOL)can be significantly decreased,survival may be impacted,and medical expenses may *** is estimated that at least 5%cancer patients might be suffering from bone *** 2016,we published the Comprehensive Guidelines for the Diagnosis and Treatment of Bone *** then,the therapeutic outcomes for patients have gradually *** life expectancy is a major determinant of surgical intervention,the strategy should be modified if the prolongation of survival is to be *** To monitor how bone metastasis treatment has changed before and after launch of our guidelines for bone *** For advanced cancer patients with bone metastasis who visited the Department of Clinical Oncology at Akita University hospital between 2012 and 2023,parameters including the site and number of bone metastases,laboratory data,and survival time,were extracted from electronic medical records and the Katagiri score was *** association with survival was determined for each *** Data from 136 patients were *** 1-year survival rate for the poor prognosis group with a higher Katagiri score was 20.0%in this study,which was 6%and an apparent improvement from 2014 when the scoring system was *** factors significantly affecting survival included five or more bone metastases than less(P=0.0080),and treatment with chemotherapy(P<0.001),bone modifying agents(P=0.0175)and immune checkpoint inhibitors(P=0.0128).In recent years,advances in various treatment methods have extended the survival period for patients with advanced *** is necessary not only to simply extend survival time,but also to maintain ADL and improve *** Various therapeutic interventions including surgical approach for bone metastasis,which is a disorder of locomotor organs,are increasingly *** and scoring system for p

关键词： Bone metastasis New Katagiri scoring system Prognosis Immune check point inhibitors Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture

引用

World Journal of Gastrointestinal Oncology 2021年第4期13卷 295-304页

作者： Taichi Yoshida Kentaro Takahashi Kengo Shibuya Osamu Muto Yuko Yoshida daiki taguchi Kazuhiro Shimazu Koji Fukuda Fuminori Ono Kyoko Nomura Hiroyuki Shibata Department of Clinical Oncology Akita University Graduate School of MedicineAkita 010-8543Japan Department of Gastroenterological Surgery Nakadori General HospitalAkita 010-8577Japan Department of Gastroenterology Akita Kousei MedicalAkita 010-0948Japan Department of Medical Oncology Akita Red Cross HospitalAkita 010-1495Japan Department of Surgery Omagari Kousei Medical CenterAkita 014-0027Japan Department of Environmental Health Science and Public Health Akita University Graduate School of MedicineAkita 010-8543Japan

BACKGROUND Angiogenesis inhibitors(AIs)combination with cytotoxic chemotherapy is a promising treatment for patients with colorectal cancer(CRC).Aflibercept(AFL)is an option for second-line treatment of CRC,according to the‘VELOUR’***,we can choose from three AIs,including bevacizumab,ramucirumab,and *** AIs can be used in subsequent treatment because of their distinctive mechanisms of *** addressed the uncertainty regarding AFL efficacy and safety in heavily-treated patients by comparing outcomes of survival treatment with second-line *** To determine and compare the efficacy and safety profiles of AFL in the secondline and salvage therapy *** Clinical data of 41 patients with advanced CRC who received intravenous AFL combined with the folinic acid-fluorouracil-irinotecan(FOLFIRI)regimen were collected retrospectively from six institutions in Japan,for the period from May 2017 to March *** characteristics collected included age,sex,tumor location,RAS and RAF status,metastatic sites,number of previous treatment cycles,therapeutic response,adverse events,duration of previous AI treatment,and survival *** end points were time to AFL treatment failure(aTTF)and median survival time post-AFL(aMST).Statistical analyses were performed to compare the efficacy and safety in the second-line setting with those of the salvage therapy setting,which was defined as the days since the end of secondline *** All 41 patients who received AFL+FOLFIRI for advanced CRC had metastatic or unresectable ***-two patients received AFL in the second-line setting and nineteen in the salvage therapy *** patient characteristics were similar in the two groups,except for two *** median duration of the previous AI administration was shorter in the second-line patients compared with that in the salvage therapy patients(144 d vs 323 d,P=0.006).In the second-line and salvage therapy groups,the objectiv

关键词： Colorectal cancer Aflibercept Second-line chemotherapy Folinic acidfluorouracil-irinotecan Palliative chemotherapy Observational cohort study

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：